sam patrick posted an articleBiopharma research is an important source of jobs, tax revenue and research spending in SC see more
New findings show biopharma research companies a source of jobs, tax revenue and research spending in state
GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.
The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.
“Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”
Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.
“One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”
In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.
“Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.
About SC BIO
SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state. With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world. Visit us at SCBIO.org.
sam patrick posted an articlePrisma Health-Upstate’s Cancer Institute Awarded $8 million NCI grant to expand clinical trials for cancer treatmentsClinical trials are saving lives in South Carolina see more
When he was diagnosed with stage 4 lung cancer in 2011, Jimmy Alexander wasn’t expected to live more than a year.
So doctors enrolled him in a clinical trial of a new chemotherapy cocktail hoping it might make a difference.
Eight years later, the Simpsonville man is still enjoying Clemson football and time with his family, including two daughters, five grandchildren and six great-grandchildren.
And now the program that helped Alexander is being expanded into the Midlands with an $8.2 million grant awarded Friday by the National Cancer Institute’s Community Oncology Program, or NCORP.
“People just don’t realize what clinicals may be able to do,” Alexander said. “They can be a lifesaver.”
Clinical trials are conducted to determine whether a treatment works while offering patients a shot at experimental therapies that aren’t otherwise available through normal channels.
They provide physicians with new weapons in the battle against cancer, said Dr. Larry Gluck, medical director of Prisma Health-Upstate’s Cancer Institute in Greenville, which was awarded the grant.
“Because of our NCI designation and support,” he said, “we can offer hundreds of leading-edge clinical trials that can provide treatments to patients years before approval by the FDA for general use.”
More than 300 clinical trials are underway at Prisma’s Cancer Institute at any time and the hospital has been awarded more than $30 million in NCI grants since 1995, according to Prisma, formerly Greenville Health System.
“What we learn from one patient helps that patient – but also many many more,” said Dr. Jeff Giguere, a Prisma oncologist.
“A unique aspect of research via the NCORP grant is that it interrogates every point on the cancer continuum from diagnosis, treatment, supportive care," he said, "as well as proactively evaluates cancer prevention and more effective and efficient ways of delivering cancer care.”
The latest six-year grant will enable trials for lymphoma, leukemia and solid tumors to begin in the Midlands this fall.
“Our goal ... is to continue to serve our Upstate patients with strengthened options here and extend our reach and expertise to the legacy Palmetto Health institutions via Prisma Health,” said Giguere. “We hope to meet an unmet need for our state.”
There was no guarantee when Alexander was enrolled in the trial that he would benefit from the drugs. But the 78-year-old said he would have participated anyway in case it would help others.
“If whatever I am doing helps other people, I was glad to do it,” he said. “But here I am eight years later.”
Alexander said his cancer is stable, thanks to a weekly infusion of a drug called Erbitux, which is provided through the trial.
Fortunately, the retired engineer was able to live to see a great-granddaughter born seven months ago.
“I’m doing pretty good. The only problem I have is old age,” he says with a chuckle. “I’m still around to play with her. It’s a great, great thing.”